JPWO2022138987A1 - - Google Patents
Info
- Publication number
- JPWO2022138987A1 JPWO2022138987A1 JP2022571730A JP2022571730A JPWO2022138987A1 JP WO2022138987 A1 JPWO2022138987 A1 JP WO2022138987A1 JP 2022571730 A JP2022571730 A JP 2022571730A JP 2022571730 A JP2022571730 A JP 2022571730A JP WO2022138987 A1 JPWO2022138987 A1 JP WO2022138987A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024113814A JP7738869B2 (ja) | 2021-04-14 | 2024-07-17 | ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021068672 | 2021-04-14 | ||
| JP2021068672 | 2021-04-14 | ||
| JP2021105802 | 2021-06-25 | ||
| JP2021105802 | 2021-06-25 | ||
| JP2021153819 | 2021-09-22 | ||
| JP2021153819 | 2021-09-22 | ||
| PCT/JP2022/006495 WO2022138987A1 (ja) | 2021-04-14 | 2022-02-17 | ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024113814A Division JP7738869B2 (ja) | 2021-04-14 | 2024-07-17 | ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2022138987A1 true JPWO2022138987A1 (https=) | 2022-06-30 |
| JPWO2022138987A5 JPWO2022138987A5 (https=) | 2023-01-24 |
| JP7530596B2 JP7530596B2 (ja) | 2024-08-08 |
Family
ID=82159864
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525557A Active JP7105430B1 (ja) | 2021-04-14 | 2022-02-17 | ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物 |
| JP2022571730A Active JP7530596B2 (ja) | 2021-04-14 | 2022-02-17 | ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物 |
| JP2024113814A Active JP7738869B2 (ja) | 2021-04-14 | 2024-07-17 | ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525557A Active JP7105430B1 (ja) | 2021-04-14 | 2022-02-17 | ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024113814A Active JP7738869B2 (ja) | 2021-04-14 | 2024-07-17 | ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US12559474B2 (https=) |
| EP (2) | EP4122926B1 (https=) |
| JP (3) | JP7105430B1 (https=) |
| KR (2) | KR20230159812A (https=) |
| CN (6) | CN115850249B (https=) |
| AU (1) | AU2022204775B2 (https=) |
| CA (1) | CA3195272C (https=) |
| CL (1) | CL2023003041A1 (https=) |
| CO (1) | CO2022016323A2 (https=) |
| DK (1) | DK4122926T3 (https=) |
| ES (1) | ES3038833T3 (https=) |
| FI (1) | FI4122926T3 (https=) |
| HR (1) | HRP20250770T1 (https=) |
| HU (1) | HUE072435T2 (https=) |
| IL (1) | IL298794B2 (https=) |
| LT (1) | LT4122926T (https=) |
| MX (1) | MX2022014458A (https=) |
| PH (1) | PH12022553603A1 (https=) |
| PL (1) | PL4122926T3 (https=) |
| PT (1) | PT4122926T (https=) |
| RS (1) | RS66997B1 (https=) |
| SI (1) | SI4122926T1 (https=) |
| SM (1) | SMT202500268T1 (https=) |
| TW (1) | TWI815396B (https=) |
| WO (2) | WO2022138988A1 (https=) |
| ZA (1) | ZA202212526B (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT4122926T (lt) * | 2021-04-14 | 2025-07-25 | Shionogi & Co., Ltd. | Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija |
| JP2024178473A (ja) * | 2021-09-03 | 2024-12-25 | 塩野義製薬株式会社 | ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物 |
| WO2023054292A1 (ja) * | 2021-09-28 | 2023-04-06 | 塩野義製薬株式会社 | トリアジン誘導体を含有する医薬組成物 |
| AU2022353486A1 (en) * | 2021-09-28 | 2024-05-02 | National University Corporation Hokkaido University | Pharmaceutical composition containing triazine derivative |
| CN116782904A (zh) * | 2021-09-28 | 2023-09-19 | 盐野义制药株式会社 | 含有三嗪衍生物的医药组合物 |
| JP7261529B1 (ja) | 2021-11-24 | 2023-04-20 | 塩野義製薬株式会社 | ウイルス増殖阻害作用を有するトリアジン誘導体の製造方法 |
| EP4289432A4 (en) * | 2021-11-24 | 2025-01-15 | Shionogi & Co., Ltd | PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES |
| CN116514734A (zh) * | 2021-11-24 | 2023-08-01 | 盐野义制药株式会社 | 三嗪衍生物的制造方法和含有三嗪衍生物的口服给与的制剂 |
| US20250025459A1 (en) * | 2021-11-26 | 2025-01-23 | Shionogi & Co., Ltd. | Covid-19 treatment medicine characterized by combining 3cl protease inhibitor and covid-19 treatment drug |
| WO2023054732A2 (ja) * | 2022-01-19 | 2023-04-06 | 塩野義製薬株式会社 | 新型コロナウイルス感染症治療用医薬 |
| WO2023165459A1 (en) * | 2022-03-01 | 2023-09-07 | Fochon Biosciences , Ltd. | Compounds as sars-cov-2 inhibitors |
| US11655240B1 (en) | 2022-05-10 | 2023-05-23 | Beijing Grand Johamu Pharmaceutical Company, Ltd. | Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases |
| US20230302005A1 (en) * | 2022-03-25 | 2023-09-28 | Beijing Grand Johamu Pharmaceutical Company, Ltd. | Active pharmaceutical ingredient, preparation method thereof, and pharmaceutical composition including the same |
| JP7624093B2 (ja) | 2022-04-08 | 2025-01-29 | 塩野義製薬株式会社 | ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物 |
| CN114805314B (zh) * | 2022-04-20 | 2023-12-15 | 杭州国瑞生物科技有限公司 | 一种恩赛特韦的合成方法 |
| CN117126141A (zh) * | 2022-05-25 | 2023-11-28 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物及其制备和应用 |
| WO2023227117A1 (zh) * | 2022-05-27 | 2023-11-30 | 广州国家实验室 | 3c样蛋白酶抑制剂 |
| WO2023226679A1 (zh) * | 2022-05-27 | 2023-11-30 | 广州国家实验室 | 3c样蛋白酶抑制剂 |
| CN117159556A (zh) * | 2022-05-27 | 2023-12-05 | 北京远大九和药业有限公司 | 一种药物组合物及其制备方法和用途 |
| CN117122601A (zh) * | 2022-05-27 | 2023-11-28 | 北京远大九和药业有限公司 | 包含化合物与富马酸的结晶形式的药物组合物及其制备方法和用途 |
| WO2023227118A1 (zh) * | 2022-05-27 | 2023-11-30 | 广州国家实验室 | 3c样蛋白酶抑制剂 |
| CN117186077A (zh) * | 2022-06-01 | 2023-12-08 | 陕西盘龙药业集团股份有限公司 | 一种3-三唑基甲基-1,3,5-三嗪-2,4-二酮类化合物及其制备方法和应用 |
| WO2024009120A1 (en) * | 2022-07-08 | 2024-01-11 | Ascletis Bioscience Co., Ltd. | Triazine derivatives and methods of use thereof |
| CN115490681B (zh) * | 2022-07-08 | 2023-04-18 | 歌礼生物科技（杭州）有限公司 | 三嗪衍生物 |
| CN117402144B (zh) * | 2022-07-14 | 2026-03-06 | 广东东阳光药业股份有限公司 | 一种3cl蛋白酶抑制剂的制备方法 |
| CN117402185A (zh) * | 2022-07-14 | 2024-01-16 | 广东东阳光药业股份有限公司 | 三嗪类化合物及其在药物中的应用 |
| CN114989048B (zh) * | 2022-07-19 | 2023-05-23 | 郑州大学 | 环丁-1-烯胺类化合物及其制备方法和在抗ⅱ型登革病毒药物中的应用 |
| CN114933594A (zh) * | 2022-07-20 | 2022-08-23 | 北京科翔中升医药科技有限公司 | 一种氟代三嗪类化合物、药物组合物及用途 |
| CN117466873A (zh) * | 2022-07-29 | 2024-01-30 | 广东东阳光药业股份有限公司 | 嘧啶类化合物及其在药物中的应用 |
| CN115260167B (zh) * | 2022-08-01 | 2025-01-21 | 陕西盘龙药业集团股份有限公司 | 一种3-四唑基甲基-1,3,5-三嗪-2,4-二酮类化合物及其制备方法和应用 |
| CN115109042B (zh) * | 2022-08-30 | 2023-05-26 | 北京科翔中升医药科技有限公司 | 三嗪类化合物或其可药用的盐、药物组合物和用途 |
| CN115504968B (zh) * | 2022-11-21 | 2023-04-18 | 歌礼生物科技（杭州）有限公司 | 三嗪衍生物 |
| CN115819407A (zh) * | 2022-12-13 | 2023-03-21 | 浙江乐普药业股份有限公司 | 一种Ensitrelvir类似物及其制备方法和抗新冠用途 |
| CN115785080B (zh) * | 2022-12-16 | 2024-10-11 | 陕西盘龙药业集团股份有限公司 | 一种尿嘧啶母核类化合物及其制备方法和应用 |
| IL321635A (en) | 2022-12-23 | 2025-08-01 | Meiji Seika Pharma Co Ltd | The aftermath of avermectin |
| CN115991700B (zh) * | 2023-01-20 | 2025-07-18 | 厦门蔚扬药业有限公司 | 一种含硒的三嗪衍生物及其制备方法和用途 |
| CN116621817B (zh) * | 2023-07-20 | 2023-09-29 | 爱斯特（成都）生物制药股份有限公司 | 一种富马酸恩赛特韦的晶型及其制备方法、药物组合物和用途 |
| WO2025058977A1 (en) * | 2023-09-11 | 2025-03-20 | Vir Biotechnology, Inc. | Modulators of coronavirus 3c-like protease and uses thereof |
| AU2024309726A1 (en) * | 2023-10-05 | 2026-04-16 | Shionogi & Co., Ltd. | Preparation containing uracil derivative |
| AU2024307335A1 (en) * | 2023-10-05 | 2026-04-16 | Shionogi & Co., Ltd. | Pharmaceutical composition containing uracil derivative |
| WO2025125695A2 (en) | 2024-12-17 | 2025-06-19 | Medchemica Consultancy Ltd | Chemical compoundsid50000167790940 p. doc 2025-05-07 filing no.:19 |
Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02138266A (ja) * | 1988-05-17 | 1990-05-28 | Synthelabo Sa | ６‐フェニル‐３‐（ピペラジニルアルキル）‐２，４（１ｈ，３ｈ）‐ピリミジンジオン誘導体 |
| JPH04330072A (ja) * | 1990-02-15 | 1992-11-18 | Takeda Chem Ind Ltd | ピリミジンジオン誘導体 |
| JP2003520856A (ja) * | 2000-01-25 | 2003-07-08 | ニューロクライン バイオサイエンシーズ， インコーポレイテッド | 性腺刺激ホルモン放出ホルモンレセプタアンタゴニストおよびそれに関連した方法 |
| JP2005263780A (ja) * | 2004-03-15 | 2005-09-29 | Syrrx Inc | ジペプチジルペプチダーゼ阻害剤 |
| JP2007509947A (ja) * | 2003-10-31 | 2007-04-19 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ２ｂアデノシン受容体アンタゴニスト |
| JP2008534500A (ja) * | 2005-03-24 | 2008-08-28 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | プロキネチシン１受容体アンタゴニスト |
| JP2009508873A (ja) * | 2005-09-16 | 2009-03-05 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| JP2009531456A (ja) * | 2006-03-28 | 2009-09-03 | 武田薬品工業株式会社 | （ｒ）−３−アミノピペリジン二塩酸塩の調製 |
| JP2011502154A (ja) * | 2007-10-30 | 2011-01-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | アミノヘテロアリールを含むプロキネチシン１受容体拮抗物質連邦政府支援研究又は開発に関する陳述下に記述される本発明の研究及び開発は、連邦政府の支援によるものではない。 |
| CN102807568A (zh) * | 2011-05-31 | 2012-12-05 | 江苏正大天晴药业股份有限公司 | 噻二唑衍生物类dpp-iv抑制剂 |
| JP2013530231A (ja) * | 2010-06-28 | 2013-07-25 | ヤンセン ファーマシューティカ エヌ．ベー． | 鎮痛処置用プロキネチシン１受容体アンタゴニスト |
| CN104109147A (zh) * | 2014-06-21 | 2014-10-22 | 安徽省逸欣铭医药科技有限公司 | 羟基脒基苯类衍生物及其制备方法和医药用途 |
| JP2016534027A (ja) * | 2013-10-25 | 2016-11-04 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | ピリジンのケトン誘導体、それらの製造方法、およびそれらの医薬適用 |
| US20170158704A1 (en) * | 2014-08-29 | 2017-06-08 | The University Of Tokyo | Pyrimidinone derivative having autotaxin-inhibitory activity |
| JP2019094314A (ja) * | 2017-11-28 | 2019-06-20 | 日産化学株式会社 | トリアジン−２，４−ジオン誘導体及びその製造方法 |
| JP7105430B1 (ja) * | 2021-04-14 | 2022-07-25 | 塩野義製薬株式会社 | ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0442473B1 (en) | 1990-02-15 | 1998-08-19 | Takeda Chemical Industries, Ltd. | Pyrimidinedione derivatives, their production and use |
| US7462594B2 (en) * | 2003-12-31 | 2008-12-09 | Taigen Biotechnology Co., Ltd. | Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases |
| CN1926128A (zh) * | 2004-03-15 | 2007-03-07 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| WO2007007161A2 (en) * | 2005-07-08 | 2007-01-18 | Orchid Research Laboratories Limited | Novel bio-active derivatives |
| CN100502868C (zh) * | 2005-11-18 | 2009-06-24 | 北京大学 | 非肽类sars冠状病毒3cl蛋白酶抑制剂及其用途 |
| WO2007079163A2 (en) * | 2005-12-29 | 2007-07-12 | Janssen Pharmaceutica N.V. | Prokineticin 1 receptor antagonists |
| JP5140154B2 (ja) * | 2007-06-27 | 2013-02-06 | アストラゼネカ・アクチエボラーグ | ピラジノン誘導体および肺疾患の処置におけるそれらの使用 |
| PL2399910T3 (pl) | 2009-02-13 | 2014-09-30 | Shionogi & Co | Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je |
| EP2585068A1 (en) * | 2010-06-28 | 2013-05-01 | Janssen Pharmaceutica, N.V. | Prokineticin 1 receptor antagonists for the treatment of pain |
| WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| CN103153968B (zh) | 2010-08-10 | 2016-02-03 | 盐野义制药株式会社 | 三唑衍生物及含有其的具有镇痛作用的药物组合物 |
| JP6075621B2 (ja) | 2010-08-10 | 2017-02-08 | 塩野義製薬株式会社 | 新規複素環誘導体およびそれらを含有する医薬組成物 |
| CN103159665B (zh) * | 2011-12-09 | 2017-01-25 | 天津市国际生物医药联合研究院 | 对sars冠状病毒主蛋白酶具有抑制作用的靛红‑5‑酰胺类抑制剂 |
| TW201331188A (zh) * | 2011-12-15 | 2013-08-01 | Shionogi & Co | 經取代之三□衍生物及含有其之醫藥組成物 |
| WO2013118855A1 (ja) | 2012-02-09 | 2013-08-15 | 塩野義製薬株式会社 | 複素環および炭素環誘導体 |
| TWI637949B (zh) | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| JP2016079168A (ja) * | 2014-10-17 | 2016-05-16 | 塩野義製薬株式会社 | ９員縮合環誘導体 |
| TWI700284B (zh) * | 2015-05-29 | 2020-08-01 | 日商塩野義製藥股份有限公司 | 具有ｈｉｖ複製抑制作用之含氮３環性衍生物 |
| TW201817714A (zh) * | 2016-08-30 | 2018-05-16 | 英商葛蘭素史密斯克藍智慧財產權有限公司 | 抑制3c及3cl蛋白酶之化合物及其使用方法 |
| PH12021552872A1 (en) | 2020-04-05 | 2022-03-21 | Pfizer | Compounds and methods for the treatment of covid-19 |
| CN112516122A (zh) * | 2020-04-21 | 2021-03-19 | 洪楠方 | 苏拉明在制备预防或治疗冠状病毒相关疾病药物中的用途 |
| CA3188794A1 (en) * | 2020-08-11 | 2022-02-17 | William FITZSIMMONS | Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| EP4282420A4 (en) * | 2021-01-20 | 2024-11-27 | National University Corporation Hokkaido University | ANTIVIRAL AGENT |
| EP4313097A4 (en) * | 2021-03-29 | 2025-03-19 | Shireen Nature Company for General Trading, Ltd. | Willow extract and its use in treating coronavirus infection, inflammation, and associated medical conditions |
| CN113801097B (zh) | 2021-09-27 | 2022-11-22 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物、其制备方法及用途 |
| CN113735838B (zh) | 2021-09-27 | 2022-07-08 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物、其制备方法及用途 |
| CN113620888B (zh) | 2021-09-27 | 2023-06-06 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物及其制备方法和应用 |
| CN113666914B (zh) | 2021-09-27 | 2022-06-07 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物及其制备方法和用途 |
| CN113773300B (zh) | 2021-09-27 | 2022-10-11 | 成都施贝康生物医药科技有限公司 | 磺酰胺类化合物、其制备方法及用途 |
| WO2023054292A1 (ja) | 2021-09-28 | 2023-04-06 | 塩野義製薬株式会社 | トリアジン誘導体を含有する医薬組成物 |
| AU2022353486A1 (en) * | 2021-09-28 | 2024-05-02 | National University Corporation Hokkaido University | Pharmaceutical composition containing triazine derivative |
| CN116782904A (zh) * | 2021-09-28 | 2023-09-19 | 盐野义制药株式会社 | 含有三嗪衍生物的医药组合物 |
| EP4289432A4 (en) * | 2021-11-24 | 2025-01-15 | Shionogi & Co., Ltd | PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES |
| WO2023054732A2 (ja) * | 2022-01-19 | 2023-04-06 | 塩野義製薬株式会社 | 新型コロナウイルス感染症治療用医薬 |
| CN117069706A (zh) * | 2022-05-10 | 2023-11-17 | 北京远大九和药业有限公司 | 一种化合物的结晶形式及其制备方法和用途 |
-
2022
- 2022-02-17 LT LTEPPCT/JP2022/006495T patent/LT4122926T/lt unknown
- 2022-02-17 CN CN202210983564.6A patent/CN115850249B/zh active Active
- 2022-02-17 AU AU2022204775A patent/AU2022204775B2/en active Active
- 2022-02-17 CN CN202410458057.XA patent/CN118359592A/zh active Pending
- 2022-02-17 JP JP2022525557A patent/JP7105430B1/ja active Active
- 2022-02-17 CA CA3195272A patent/CA3195272C/en active Active
- 2022-02-17 JP JP2022571730A patent/JP7530596B2/ja active Active
- 2022-02-17 ES ES22733282T patent/ES3038833T3/es active Active
- 2022-02-17 WO PCT/JP2022/006496 patent/WO2022138988A1/ja not_active Ceased
- 2022-02-17 KR KR1020237002784A patent/KR20230159812A/ko active Pending
- 2022-02-17 US US17/790,358 patent/US12559474B2/en active Active
- 2022-02-17 PT PT227332822T patent/PT4122926T/pt unknown
- 2022-02-17 EP EP22733282.2A patent/EP4122926B1/en active Active
- 2022-02-17 PL PL22733282.2T patent/PL4122926T3/pl unknown
- 2022-02-17 DK DK22733282.2T patent/DK4122926T3/da active
- 2022-02-17 SI SI202230156T patent/SI4122926T1/sl unknown
- 2022-02-17 EP EP24168486.9A patent/EP4400502A3/en active Pending
- 2022-02-17 CN CN202311797713.0A patent/CN117820248A/zh active Pending
- 2022-02-17 CN CN202310437344.8A patent/CN116650498B/zh active Active
- 2022-02-17 SM SM20250268T patent/SMT202500268T1/it unknown
- 2022-02-17 HR HRP20250770TT patent/HRP20250770T1/hr unknown
- 2022-02-17 IL IL298794A patent/IL298794B2/en unknown
- 2022-02-17 RS RS20250670A patent/RS66997B1/sr unknown
- 2022-02-17 PH PH1/2022/553603A patent/PH12022553603A1/en unknown
- 2022-02-17 MX MX2022014458A patent/MX2022014458A/es unknown
- 2022-02-17 CN CN202210742186.2A patent/CN115073431B/zh active Active
- 2022-02-17 CN CN202280000918.9A patent/CN115038696A/zh active Pending
- 2022-02-17 FI FIEP22733282.2T patent/FI4122926T3/fi active
- 2022-02-17 KR KR1020227018680A patent/KR102494188B1/ko active Active
- 2022-02-17 HU HUE22733282A patent/HUE072435T2/hu unknown
- 2022-02-17 WO PCT/JP2022/006495 patent/WO2022138987A1/ja not_active Ceased
- 2022-04-13 TW TW111113943A patent/TWI815396B/zh active
- 2022-04-29 US US17/733,366 patent/US11814368B2/en active Active
- 2022-11-15 CO CONC2022/0016323A patent/CO2022016323A2/es unknown
- 2022-11-16 ZA ZA2022/12526A patent/ZA202212526B/en unknown
-
2023
- 2023-10-11 CL CL2023003041A patent/CL2023003041A1/es unknown
-
2024
- 2024-07-17 JP JP2024113814A patent/JP7738869B2/ja active Active
Patent Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02138266A (ja) * | 1988-05-17 | 1990-05-28 | Synthelabo Sa | ６‐フェニル‐３‐（ピペラジニルアルキル）‐２，４（１ｈ，３ｈ）‐ピリミジンジオン誘導体 |
| JPH04330072A (ja) * | 1990-02-15 | 1992-11-18 | Takeda Chem Ind Ltd | ピリミジンジオン誘導体 |
| JP2003520856A (ja) * | 2000-01-25 | 2003-07-08 | ニューロクライン バイオサイエンシーズ， インコーポレイテッド | 性腺刺激ホルモン放出ホルモンレセプタアンタゴニストおよびそれに関連した方法 |
| JP2007509947A (ja) * | 2003-10-31 | 2007-04-19 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ２ｂアデノシン受容体アンタゴニスト |
| JP2005263780A (ja) * | 2004-03-15 | 2005-09-29 | Syrrx Inc | ジペプチジルペプチダーゼ阻害剤 |
| JP2008534500A (ja) * | 2005-03-24 | 2008-08-28 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | プロキネチシン１受容体アンタゴニスト |
| JP2009508873A (ja) * | 2005-09-16 | 2009-03-05 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| JP2009531456A (ja) * | 2006-03-28 | 2009-09-03 | 武田薬品工業株式会社 | （ｒ）−３−アミノピペリジン二塩酸塩の調製 |
| JP2011502154A (ja) * | 2007-10-30 | 2011-01-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | アミノヘテロアリールを含むプロキネチシン１受容体拮抗物質連邦政府支援研究又は開発に関する陳述下に記述される本発明の研究及び開発は、連邦政府の支援によるものではない。 |
| JP2013530231A (ja) * | 2010-06-28 | 2013-07-25 | ヤンセン ファーマシューティカ エヌ．ベー． | 鎮痛処置用プロキネチシン１受容体アンタゴニスト |
| CN102807568A (zh) * | 2011-05-31 | 2012-12-05 | 江苏正大天晴药业股份有限公司 | 噻二唑衍生物类dpp-iv抑制剂 |
| JP2016534027A (ja) * | 2013-10-25 | 2016-11-04 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドＳｈａｎｇｈａｉ Ｈｅｎｇｒｕｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | ピリジンのケトン誘導体、それらの製造方法、およびそれらの医薬適用 |
| CN104109147A (zh) * | 2014-06-21 | 2014-10-22 | 安徽省逸欣铭医药科技有限公司 | 羟基脒基苯类衍生物及其制备方法和医药用途 |
| US20170158704A1 (en) * | 2014-08-29 | 2017-06-08 | The University Of Tokyo | Pyrimidinone derivative having autotaxin-inhibitory activity |
| JP2019094314A (ja) * | 2017-11-28 | 2019-06-20 | 日産化学株式会社 | トリアジン−２，４−ジオン誘導体及びその製造方法 |
| JP7105430B1 (ja) * | 2021-04-14 | 2022-07-25 | 塩野義製薬株式会社 | ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物 |
Non-Patent Citations (4)
| Title |
|---|
| BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, JPN6023042850, 2009, pages 2661 - 2663, ISSN: 0005349487 * |
| LAI,Z. ET AL., EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 83, JPN6022015496, 2014, pages 547 - 560, ISSN: 0005349484 * |
| REGISTRY[ONLINE], JPN7022001890, 6 December 2011 (2011-12-06), ISSN: 0005349486 * |
| REGISTRY[ONLINE], JPN7022001891, 2 December 2011 (2011-12-02), ISSN: 0005349485 * |
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221006 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221006 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231017 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231214 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240409 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240618 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240717 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7530596 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |